Table 5.

Comparison of relevant studies of irinotecan-based chemotherapy in patients with ED SCLC

	Present study	Noda et al. [11]	Lara et al. [12]	Hanna et al. [13]
Regimen	Irinotecan 65 mg/m2 D 1,8	Irinotecan 60 mg/m2 D 1,8,15	Irinotecan 60 mg/m2 D 1,8,15	Irinotecan 65 mg/m2 D 1,8
	Cisplatin 70 mg/m2 D 1	Cisplatin 60 mg/m2 D 1	Cisplatin 60 mg/m2 D 1	Cisplatin 30 mg/m2 D 1,8
	every 3 wk	every 4 wk	every 4 wk	every 3 wk
No. of patients	362	154	651	331
Median OS (mo)	10.9	12.8	9.9	9.3
Median PFS (mo)	6.5	6.9	5.8	4.1
Response rate (%)	62.4	65.0	60.0	48.0
Grade 3/4 neutropenia (%)	62.3	65.3	34.0	36.2
Grade 3/4 diarrhea (%)	10.2	16.0	19.0	21.3

ED, extensive-disease; SCLC, small-cell lung cancer; D, day; OS, overall survival; PFS, progression-free survival.